Various receptor tyrosine kinase (RTK) inhibitors are currently under clinical investigation in patients with glioblastoma, including agents targeting the EphA3 receptor, EGFR, and VEGF (Table S6) [4]. Here, VEGFA is linked to glioblastoma.